Smectite for acute infectious diarrhoea in children.

CONCLUSIONS: Based on low-certainty evidence, smectite used as an adjuvant to rehydration therapy may reduce the duration of diarrhoea in children with acute infectious diarrhoea by a day; may increase cure rate by day 3; and may reduce stool output, but has no effect on hospitalization rates or need for intravenous therapy. PMID: 29693719 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research

Related Links:

[IPS] Brazzaville -When faced with a crisis, our natural reaction is to deal with its immediate threats. Ateka* came to the make-shift clinic with profuse diarrhoea: they diagnosed cholera. The urgent concern in the midst of that humanitarian crisis was to treat the infection and send her home as quickly as possible. But she came back to the treatment centre a few days later - not for cholera, but because she was suffering from severe acute malnutrition. Doctors had saved her life but not restored her health. And there were
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
[RotaCouncil] A major new study has shown that rotavirus vaccination reduced infant diarrhoea deaths by 34% in rural Malawi, a region with high levels of child deaths.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
In conclusion, the present study demonstrated the anti‑fibrotic potential of BMMSCs in BA mice, which may provide a novel approach to ameliorate the fibrotic response in BA patients. PMID: 30106103 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Condition:   Meningococcal Infection Interventions:   Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine;   Biological: Meningococcal group B vaccine;   Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine;   Biological: Human rotavirus RIX4414 strain vaccine;   Biological: Pneumococcal 13-valent polysaccharide conjugate vaccine Sponsor:   Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsThe relief of key OAB symptoms produced by mirabegron 50 mg is significantly better than placebo, and similar to a range of common antimuscarinics, with the benefit of significantly fewer bothersome anticholinergic side effects such as dry mouth. Combination treatment of solifenacin 5 mg plus mirabegron 25 or 50 mg appears to provide an efficacy benefit compared with mirabegron 50 mg, with the expected side effects of individual antimuscarinics.Patient summaryThis study assessed the efficacy and tolerability of different drug treatments for OAB. Mirabegron 50 mg was as effective as antim...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Condition:   Meningococcal Infection Interventions:   Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine;   Biological: Meningococcal group B vaccine;   Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine;   Biological: Human rotavirus RIX4414 strain vaccine;   Biological: Pneumococcal 13-valent polysaccharide conjugate vaccine Sponsor:   Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A hyperendemic rotavirus season was expected after a low-endemic 2014 season in the Netherlands. Rotavirus detections were however similar in 2015 and lower in 2016 compared with 2010–2013. Gastroenteritis consultation rates were also similar in 2015, but the age distribution shifted to older children because of an accumulation of noninfected children. Results indicate a possible shift to a biennial rotavirus pattern.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Brief Reports Source Type: research
Conclusion: Implementation of rotavirus vaccines has substantially reduced diarrhea-associated health care utilization in US children under 5 years of age. Both vaccines provided good and enduring protection through the fourth year of life against rotavirus hospitalizations.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Vaccine Reports Source Type: research
ConclusionMELF was found to protect pancreatic β cells function from STZ-induced apoptosis and autophagy in in vitro and in vivo.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
DISCUSSION: This small, prospective case series suggests that, in the short term, HDR brachytherapy is safe and well tolerated in IBD patients. Therefore, IBD should not automatically disqualify patients from, at least, HDR brachytherapy. The reason why these results differ from previous LDR studies possibly reflects the benefit of inverse planning, which more readily achieves rectal dose constraints in HDR brachytherapy. PMID: 30099986 [PubMed - in process]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Oncol (R Coll Radiol) Source Type: research
More News: Breastfed | Children | Conferences | Constipation | Databases & Libraries | Diarrhoea | General Medicine | Infectious Diseases | IV Therapy | Rotavirus | Study